These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 28199966)

  • 1. Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials.
    Hao S; Tian W; Gao B; Jiang Y; Zhang X; Zhang S; Guo L; Zhao J; Zhang G; Hu C; Yan J; Luo D
    Oncotarget; 2017 Mar; 8(12):19923-19933. PubMed ID: 28199966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.
    Valachis A; Nearchou A; Polyzos NP; Lind P
    Int J Cancer; 2013 Nov; 133(9):2245-52. PubMed ID: 23629633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with breast cancer treated with HER2 blockade.
    Wu J; Qiu K; Zhu J; Li J; Lin Y; He Z; Li G
    Breast; 2015 Dec; 24(6):699-704. PubMed ID: 26376461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.
    Valachis A; Nearchou A; Lind P; Mauri D
    Breast Cancer Res Treat; 2012 Oct; 135(3):655-62. PubMed ID: 22875745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
    Xu ZQ; Zhang Y; Li N; Liu PJ; Gao L; Gao X; Tie XJ
    BMJ Open; 2017 Mar; 7(3):e013053. PubMed ID: 28289045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.
    Clavarezza M; Puntoni M; Gennari A; Paleari L; Provinciali N; D'Amico M; DeCensi A
    Clin Cancer Res; 2016 Sep; 22(18):4594-603. PubMed ID: 27140927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review.
    Wang C; Chen J; Xu X; Hu X; Kong D; Liang G; Wang X
    Technol Cancer Res Treat; 2020; 19():1533033820960721. PubMed ID: 32990165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
    Sabatier R; Gonçalves A
    Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer.
    Abramovitz M; Williams C; Loibl S; Leyland-Jones B
    Clin Breast Cancer; 2016 Dec; 16(6):444-455. PubMed ID: 27435628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
    Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
    Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Sotelo MJ; García-Sáenz JA; Manso L; Moreno F; Ciruelos E; Callata HR; Mendiola C; Cabezas S; Ghanem I; Díaz-Rubio E
    J Cancer Res Ther; 2014; 10(4):967-72. PubMed ID: 25579538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
    Hicks M; Macrae ER; Abdel-Rasoul M; Layman R; Friedman S; Querry J; Lustberg M; Ramaswamy B; Mrozek E; Shapiro C; Wesolowski R
    Oncologist; 2015 Apr; 20(4):337-43. PubMed ID: 25732265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
    Larsen PB; Kümler I; Nielsen DL
    Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis.
    Li H; Fu W; Gao X; Xu Q; Wu H; Tan W
    Tumour Biol; 2014 May; 35(5):4077-85. PubMed ID: 24375251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review.
    Zhang X; Zhang XJ; Zhang TY; Yu FF; Wei X; Li YS; He J
    BMC Cancer; 2014 Aug; 14():625. PubMed ID: 25164542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
    Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
    Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.